J&J vaccinations resume as FDA, CDC confident in benefit-risk profile
The FDA and CDC on Friday evening lifted the pause on J&J vaccinations after deciding that a very rare but sometimes fatal side effect does not change the fact that the vaccine’s known and potential benefits still outweigh the risks.
FDA also updated the fact sheets for vaccine recipients and providers to note the risk of blood clots and low levels of platelets, known as thrombosis with thrombocytopenia syndrome (TTS).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
